Company: PSTV
Filing Date: 2025-02-18
Form Type: 8-K
Source: 0001193125-25-028151
Chunk: 3

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-02-18
Form: 8-K
Item: Item 1.01
Chunk 3
---
 the SPEA, the Company issued to the Purchases secured convertible promissory notes in the aggregate amount of $3,188,922 (the “ Exchange Notes” and together with the Funding Notes, the “ Notes”) in exchange for cancellation of the Series A Warrants of the Purchasers, and the Purchasers entered into a second amendment to the May 2024 Purchase Agreement to eliminate the Financing Restrictions (the “ Financing Waiver”).

The terms and conditions of the Exchange Notes are substantially identical in all material respects to the Funding Notes, except that the Mandatory Conversion applies to all of the principal amount of the Exchange Notes instead of being limited to seventy-five percent, and the Maximum Amount does not apply. The Security Agreement and Subsidiary Guarantee also apply to the obligations under the Exchange Notes.

Registration Rights Agreement

In connection with the SPEA, the Company entered into a registration rights agreement (the “ Registration Rights Agreement”), dated as of the Closing Date, with the Purchasers, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “ Commission”) covering the resale of the shares of Common Stock issuable pursuant to the Notes and Warrants (the “ Registration Statement”) at the earlier of the fifteenth calendar day after the Company has filed its Annual Report on Form10-Kfor the calendar year ended December 31, 2024, or April 15, 2025 (the “ Filing Due Date”), and to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than June 30, 2025 (the “ Effectiveness Due Date”), provided, however, that the Effectiveness Due Date for the shares of common stock issuable under the Exchange Notes is the earlier of the fifteenth calendar day after the Company has filed its Annual Report on Form10-Kfor the calendar year ended December 31, 2024, or April 15, 2025. In addition, pursuant to the Registration Rights Agreement, the Company is required to use its reasonable best efforts to keep the Registration Statement continuously effective from the date on which the Commission declares the Registration Statement to be effective until such date that all Registrable Securities (as such term is defined in the Registration Rights Agreement) covered by the Registration Statement have been sold pursuant to a registration statement under the Securities Act of 1933, as amended (the “ Securities Act”), under Rule 144 as promulgated by the Commission under the Securities Act (“ Rule 144”), or otherwise